Novartis AG / Pikavation Therapeutics, Inc.

HR+/HER2- Metastatic Breast Cancer (PIK3CA-mutant)

206K US cases/yr · $1.5B Global PI3K inhibitor drug-class market, 2025 (projected $2.3B by 2033) · ~40% Share of HR+/HER2- breast cancer patients with PIK3CA mutations (targetable population)

Disease Overview

HR+/HER2- metastatic breast cancer is the largest molecular subtype of metastatic breast cancer, representing roughly two-thirds of all breast cancer diagnoses in the United States. Standard first-line treatment combines endocrine therapy with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib). However, virtually all patients eventually progress through PI3K/AKT/mTOR pathway activation, and approximately 36-40% of HR+/HER2- metastatic tumors harbor activating mutations in PIK3CA (most commonly H1047R, E545K, E542K hotspots). PIK3CA-mutant disease is associated with endocrine resistance and shorter progression-free survival. The American Cancer Society estimates approximately 316,950 invasive breast cancer diagnoses in US women for 2026, with roughly 65% classified as HR+/HER2-; of these metastatic-setting patients, the PIK3CA-mutant subset represents the targetable population for selective PI3K-alpha inhibitors such as alpelisib (Piqray) and inavolisib (Itovebi). Genomic testing via tissue or liquid-biopsy NGS is now standard-of-care at progression.

Competitive Landscape

The PIK3CA-mutant breast cancer market has two approved agents, both pan-PI3K-alpha inhibitors: Novartis' alpelisib (Piqray, approved 2019) and Roche's inavolisib (Itovebi, approved 2024). Both block mutant and wild-type PI3K-alpha, which causes dose-limiting hyperglycemia, rash, and GI toxicity that forces dose reduction or discontinuation. Piqray generated $382M in 2025 Novartis revenue (down 15% YoY due to Itovebi competition), while Itovebi is ramping rapidly after positive INAVO120 overall-survival data. A new wave of mutant-selective PI3K-alpha inhibitors aims to spare wild-type PI3K-alpha, avoiding the metabolic toxicity. Key investigational competitors include Eli Lilly's LOXO-783 (Phase 1/2, pan-mutant-selective), Relay Therapeutics' RLY-2608 (Phase 1, mutant-selective allosteric), OnKure Therapeutics' OKI-219 (Phase 1, H1047R-selective), and Scorpion Therapeutics' STX-478. SNV4818 enters this field with a pan-mutant-selective profile positioned to support combination with CDK4/6 inhibitors and endocrine therapy without tolerability-driven dose compromises.